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ABSTRACT 
 Background: Amrubicin is active in the treatment of extensive-disease small 
cell lung cancer (ED-SCLC), and carboplatin is an analogue of cisplatin with less 
non-hematological toxicity. 
 Purpose: To determine the efficacy and toxicity of amrubicin and carboplatin 
combination chemotherapy for previously untreated patients with ED-SCLC.  
 Patients and methods: Eligibility criteria were chemotherapy-naïve ED-SCLC 
patients, performance status 0-1, age ≤75, and adequate hematological, hepatic and 
renal function. Based on the phase I study, the patients received amrubicin 35 mg/m2 i.v. 
infusion on days 1,2 and 3, and carboplatin AUC 5 i.v. infusion on day 1. Four cycles of 
chemotherapy were repeated every 3 weeks.  
 Results: Thirty-five patients were enrolled and 34 patients were eligible and 
assessable for response, toxicity and survival. Patients’ characteristics were as follows: 
male/female = 26/8; performance status (PS) 0/1 = 4/30; median age (range) = 64 
(41-75); stage IV = 34.  Evaluation of responses were 6 complete response (CR), 21 
partial response (PR), and 7 stable disease (SD) (response rate 79.4%, 95%CI 
63.6-88.5%). Grade 3 and 4 leukopenia, neutropenia, and thrombocytopenia occurred in 
59%, 82%, and 26%, respectively. There were no treatment-related deaths or 
pneumonitis. Three patients experienced hypotension as an amrubicin infusion reaction. 
The median progression-free survival time was 6.5 months. The median overall survival 
time and 1-, 2- and 3-year survival rates were 15.6 months, 63%, 28% and 7%, 
respectively.  
 Conclusions: Amrubicin and carboplatin was effective and tolerable as 
chemotherapy for previously untreated patients with ED-SCLC. Further investigation of 
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amrubicin and carboplatin is warranted.
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INTRODUCTION 
Lung cancer is the leading cause of cancer deaths worldwide. It is also the 
Japanese leading cause of death, with 70,293 deaths (19.7% of all cancer deaths) in 
2011 (1). Of all lung cancer cases, approximately 20% are small cell lung cancer 
(SCLC) (2). Although this cancer is initially highly responsive to chemotherapy, the 
vast majority of patients will ultimately relapse and die of recurrent disease within 2 
years. Recently, combination chemotherapy with irinotecan and cisplatin for 
extensive-disease (ED) SCLC produced equal or more survival benefit than etoposide 
and cisplatin, the worldwide standard regimen since 1981 (3-5). The therapy provided 
2-year survival rates of only 8% to 19.5%, with a median survival time of 9.3 to 12.8 
months. Clearly, new and more effective agents against SCLC are needed. 
Amrubicin is a completely synthetic anthracycline derivative characterized by 
a 9-amino group and a simple sugar moiety. The chemical structure and acute toxicity 
of amrubicin are similar to those of doxorubicin (6, 7); however, it shows almost no 
cardiotoxicity (8, 9). Amrubicin alone and combination chemotherapy with cisplatin 
exhibited high response rates of 75.8% and 87.8% and median survival times of 11.7 
and 13.6 months in previously untreated ED-SCLC, respectively (10, 11). Carboplatin is 
a platinum derivative with less renal toxicity that caused less nausea and vomiting than 
cisplatin (12), and has been combined with other newer agents in chemotherapy for 
SCLC (13). Pharmacodynamic studies have been performed to predict the clearance and 
administer the appropriate dose of carboplatin to individual patients (14-16). 
Accordingly, we conducted a phase I study with escalating doses of amrubicin under a 
fixed AUC 5 of carboplatin, and found that a dose of 35 mg/m2 amrubicin was 
recommended in this regimen (17). In the phase I study, this regimen is associated with 
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an acceptable tolerability profile, a highly effective response rate of 73% and median 
survival time of 13.6 months.   
Based on these results, we conducted a phase II study of amrubicin and 
carboplatin therapy for previously untreated ED-SCLC. The main objectives of the 
study were to determine the efficacy and safety of this regimen.  
 
PATIENTS AND METHODS 
 The study protocol was reviewed and approved by the ethics committee of 
each institution, and written informed consent was obtained from all study participants. 
This study was an independent collaborative (unsponsored) group study. The clinical 
trial registration number is UMIN000001115. 
 
Patients and evaluation 
Eligibility criteria for patients in this study included the following: a 
histologically and/or cytologically confirmed diagnosis of ED-SCLC (19); no prior 
chemotherapy or radiotherapy; age ≤75 years; Eastern Cooperative Oncology Group 
(ECOG) performance status (PS) ≤1; life expectancy >12 weeks; adequate bone marrow 
function (leukocyte count ≥4,000/µL, platelet count ≥10.0 x 104/µL, and hemoglobin 
level ≥9.0 g/dL); serum bilirubin level ≤1.5 mg/dL; ALT and AST levels ≤2 times the 
normal upper limit; serum creatinine level ≤ the normal upper limit; and no medical 
problems severe enough to prevent compliance with the protocol.  
  
Treatment and dose escalation 
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 Based on our phase I study (17), patients received 35 mg/m2 amrubicin on 
days 1, 2 and 3, and carboplatin with a target AUC 5 mg.min/ml on day 1. Carboplatin 
was administered during a 60-min intravenous infusion of 250 ml of 5% dextrose. 
Amrubicin was diluted in 50 ml normal saline and administered as an intravenous 
injection. Granulocyte colony-stimulating factor (G-CSF) was administrated when the 
neutrophil count became <1,000/µl and was discontinued when the count recovered to 
>5,000/µl. The next cycle commenced after leukocyte and platelet counts reached at 
least 3,000/µl and 100,000/µl, respectively, and if levels fell below these limits, the next 
cycle was postponed until the counts recovered. Doses of amrubicin and carboplatin 
were reduced to 75% when grade 4 hematological toxicities occurred during the 
previous treatment cycle. In patients showing a response, this chemotherapy was 
repeated every 3 weeks for four cycles.  
 
Toxicity and response evaluation 
 Eligibility, assessibility and tumor responses were determined by external 
reviewers. Drug toxicity was graded according to the NCI Common Terminology 
Criteria for Adverse Events v3.0 (CTCAE) (18). Before the first cycle, a blood cell 
count, urinalysis, and biochemistry tests were performed to assess renal and hepatic 
function and electrolytes. This monitoring was repeated during treatment, while other 
investigations were repeated, as necessary, to evaluate marker lesions. After the 
completion of treatment, each disease was assessed and tumors restaged. Tumor 
response was classified according to Response Evaluation Criteria in Solid Tumors 
(RECIST) and tumor markers were excluded from the criteria (19). Complete response 
(CR) was defined as the complete disappearance of all clinically detectable tumors for 
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at least 4 weeks and no new lesions. Partial response (PR) was defined as at least a 30% 
decrease in the sum of the longest diameters of the target lesion, taking as reference the 
baseline sum longest diameter, the required non-progression of non-target lesions and 
no new lesions. Stable disease (SD) included the regression of target lesions insufficient 
to meet the criteria for PR, a <20% increase in the sum of the longest diameters of the 
target lesion, taking as reference the smallest sum longest diameters recorded since the 
treatment started, the required non-progression of non-target lesions and no new lesions. 
Progressive disease (PD) indicated a ≥20% increase in the sum of the longest diameters 
of target lesion, taking as reference the smallest sum longest diameter recorded since the 
treatment started and/or unequivocal progression of existing non-target lesions and/or 
the appearance of new lesions. Evaluation of the objective tumor response for all 
patients was performed by external reviewers.  
 
Statistical analysis 
 The primary endpoint of this study was the estimation of the objective 
response rate. The two-stage accrual design described by Simon was used (20). 
Assuming an overall response rate of 60% for standard therapy, a target response rate of 
80% was established. Alpha = 0.05 and beta = 0.20, and the estimated required number 
of patients was 35. The upper limit of rejection was 25 responses (CR + PR). Overall 
survival was calculated by the Kaplan-Meier method (21). 
 
RESULTS 
 Thirty-five patients from 7 institutions were enrolled in this trial between 
March 2008 and November 2011. All patients received the planned treatment and 34 
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were evaluated for toxicity, response and survival. One patient was ineligible because of 
being judged to have limited disease by the external reviewers. The baseline patient 
characteristics are shown in Table 1.  
 
Treatment administration 
 A total of 148 cycles of this therapy were administered with a median of 4 
cycles per one patient: 1 cycle in 4 patients (12%), 2 cycles in 2 (6%), 3 in 1 (3%), 4 in 
11 (32%), 5 in 3 (9%), and 6 in 13 (38%). In 4 patients who were administered only 1 
cycle, 3 patients terminated the treatment because of hypotension. The remaining 
patient terminated the treatment because of a reduction of PS. Two terminated the 
treatment after 2 cycles because of PD and severe neutropenia. The latter was treated by 
2 more cycles out of the study because the reduction dose was over the protocol. One 
patient achieved PR, but progressed and terminated the treatment after 3 cycles. The 
patients planned for 4 cycles, 16 patients were administered 5 or 6 cycles because 
continuing reduction of tumor size.  
 
Efficacy 
 Of 35 patients, 34 were assessable for response. Objective tumor response 
was observed in 27 patients, with an overall response rate of 79.4% [95% confidence 
interval (CI) 63.6% to 88.5%] (Figure 1 and Table 2). Six (18%) patients had CR. At 
the survival assessment in June 2013, six patients were still alive and the other 28 
patients had died. The progression-free survival of 34 patients is shown in Figure 2A. 
Median progression-free survival time was 6.5 months. The overall survival of 34 
10 
patients is shown in Figure 2B. Median survival time (MST) was 15.6 months and the 
1-, 2-, 3-, 4-, and 5-year survival rates were 63%, 28%, 7%, 7%, and 0%, respectively.     
 
Toxicity 
 The worst grades of hematological and non-hematological toxicities 
experienced by each patient are listed Table 3. Of the 34 patients, 28 (82%) experienced 
grade 3 or 4 hematological toxicity, and 21 (62%) experienced grade 4. The principal 
grade 3 or 4 toxicities were neutropenia and leukopenia in 28 (82%) and 20 (59%) 
patients, and the grade 4 toxicities were neutropenia, leukopenia and thrombocytopenia 
in 21 (62%), 4 (12%) and 4 (12%), respectively. The common non-hematological 
adverse events was nausea in 18 patients (53%). Hypotension was observed in 3 (9%) 




 The present amrubicin combined with carboplatin therapy for previously 
untreated patients with ED-SCLC yielded 27 responders among 34 evaluable patients 
with an overall response rate of 79.4%. Although this falls short of amrubicin/cisplatin 
(87.8%) in a phase II trial (11), it was a high response compared with standard regimens 
of irinotecan/cisplatin (48-65%) and etoposide/cisplatin (43.6%-57%) in phase III 
studies (3-5), and achieved the primary endpoint. Alternatively, the present MST of 15.6 
months was longer than with the previous three regimens, which were 13.6, 9.3-12.8, 
9.1-10.2 and 12.8 months, which were the MST of amrubicin/carboplatin for elderly 
(age ≥70) patients with ED-SCLC (22).  
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Recently, the Japanese Clinical Oncology Group (JCOG) reported a phase III 
trial of amrubicin/cisplatin for previously untreated ED-SCLC to compare combination 
therapy of irinotecan/cisplatin (23). Although the non-inferiority of amrubicin/cisplatin 
was not determined and overall survival was much worse than that of 
irinotecan/cisplatin, overall survival with the two regimens was excellent, 15.0 and 18.3 
months, respectively. Amrubicin and irinotecan have shown activity in previously 
treated patients with ED-SCLC (24-26), and this might suggest that routine additional 
use of amrubicin with irinotecan, etoposide and platinum will prolong survival in 
ED-SCLC in Japan. In this JCOG study, dose of amrubicin was reduced 40 mg/m2 to 35 
mg/m2 because of severe myelotoxicities. The MSTs of amrubicin/cisplatin arm were 
14.9 months (40 mg/m2) and 20.7 months (35 mg/m2), respectively. Considering with 
the activities of cisplatin and carboplatin and our amrubicin dose (35 mg/m2), our 
favorable MST of 15.6 months seems appropriate. 
 Based on our phase I trial (17), we used amrubicin 35 mg/m2 on days 1-3 and 
carboplatin on day 1 with a target AUC of 5 mg.min/ml in the present study. Because 
the recommended dose (RD) of single-agent amrubicin is 45 mg/m2 (27), the RD of 
amrubicin is 10 mg/m2 lower in combination with carboplatin. In combination with 
cisplatin 60 mg/m2 on day 1, the RD of amrubicin was initially 40 mg/m2 in a phase I-II 
trial (11). However, this level was too toxic and the dose of amrubicin was reduced to 
35 mg/m2 during the phase III trial (23). The present phase II trial demonstrated the 
tolerability of 35 mg/m2 amrubicin; therefore, 35mg/m2 was recommended for 
amrubicin combined with platinum.  
The main severe toxicity associated with amrubicin is myelosuppression, with 
neutropenia seen more frequently than thrombocytopenia or anemia. In the present study, 
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the incidence of grade 3 or 4 neutropenia was 82%, which is lower than the incidence of 
95.1% to 95.7% reported with amrubicin/cisplatin (11, 23). The rate of 
thrombocytopenia, which is associated with carboplatin toxicity, observed in this study 
(12%) was also lower than the incidence of 24.4% to 27.1% reported with 
amrubicin/cisplatin (11, 23). This was perhaps due to the amrubicin dose difference, 35 
mg/m2 for our study and 40 mg/m2 in cisplatin studies. Because G-CSF was 
administered to patients with grade 3 or 4 neutropenia, it was commonly used. 
Unfortunately, one of our patients died due to severe hematological toxicities in the 
third cycle in the phase I trial (17), so we determined to decrease the dose from 80% to 
75% in the next cycle in the phase II trial. Careful hematological toxicity control is 
essential in the therapeutic use of amrubicin. In most cases, myelosuppression was 
manageable with protocol-specific dose reductions, treatment delays, and G-CSF 
support, and there was no treatment-related death in the present study. The common 
non-hematological toxicity was nausea, and hypotension was observed in three patients 
(9%). Although hypersensitivity reactions to carboplatin are well-known (28), the 
hypotension in the present study was observed immediately after administration of 
amrubicin and was considered to be an infusion reaction to amrubicin. This adverse 
effect had not been reported previously but was recently reported in a Japanese trial of 
amrubicin combined with S-1 (29). Pneumonitis, which is a difficult toxicity in cancer 
chemotherapy that has also been reported with amrubicin (24, 25), was not observed.  
In conclusion, our phase II trial demonstrated the usefulness of amrubicin 
/carboplatin chemotherapy for previously untreated patients with ED-SCLC. This 
regimen is a convenient non-cisplatin treatment and is active in terms of the probability 
of response and survival compared with other regimens for SCLC. Further investigation 
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of amrubicin/carboplatin is warranted.  
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 Waterfall plots for the degree of tumor shrinkage. Most patients achieved 
tumor shrinkage. Complete and partial responses were observed 6 and 21 patients, 
respectively, and the response rate was 79.4%. 
 
Figure 2. 
A) Progression-free survival curve, and B) overall survival curve of the 34 





Table 1. Patient characteristics  
 
Characteristics  No. of patients 
 
Gender    
 Male 26 
 Female 8 
Age (years)   
 Median 64 
 Range 41-75 
Performance status (ECOG) 
 0  4 
 1  30 
Stage  
 IV 34 
    





Table 2. Tumor response  
  n CR PR SD PD Response rate (%) 
     (95% CI) 

























































































2-year survival rate: 28%
